Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[177Lu]Lu-DTPA-pivekimab
- Development stage
- Preclinical
- Lead developer
- Chinese Academy of Medical Sciences
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[177Lu]Lu-DTPA-pivekimab is an investigational radioimmunotherapy agent being developed for the treatment of Acute Myeloid Leukemia (AML). It consists of pivekimab, a monoclonal antibody that targets CD123 (the interleukin-3 receptor alpha chain), conjugated with the bifunctional chelator Bz-DTPA and radiolabeled with the beta-emitting radionuclide lutetium-177 (177Lu). CD123 is highly expressed on AML blasts and leukemic stem cells but has limited expression on normal hematopoietic counterparts, making it a suitable target for selective therapy. The mechanism of action involves the targeted delivery of beta radiation to CD123-expressing cells, inducing DNA damage and cell death through both direct irradiation and cross-fire effects. This agent is part of a radiotheranostic platform that pairs therapeutic [177Lu]Lu-DTPA-pivekimab with diagnostic [89Zr]Zr-DFO-pivekimab for PET imaging to assess target expression and monitor treatment response.
- Other names
- 177Lu-labeled pivekimab177Lu-DTPA-pivekimab
02
Targets
IL3RA (Interleukin 3 Receptor)
Beyond the preview
Go deeper on [177Lu]Lu-DTPA-pivekimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [177Lu]Lu-DTPA-pivekimab.